Stifel Nicolaus started coverage on shares of Allergan (NYSE:AGN) in a research note released on Tuesday morning, MarketBeat Ratings reports. The firm issued a hold rating and a $192.00 target price on the stock.
A number of other equities research analysts have also recently commented on AGN. Credit Suisse Group set a $214.00 price target on shares of Allergan and gave the company a buy rating in a report on Tuesday, December 19th. They noted that the move was a valuation call. ValuEngine cut shares of Allergan from a buy rating to a hold rating in a report on Sunday, December 31st. Zacks Investment Research cut shares of Allergan from a hold rating to a sell rating in a report on Tuesday, January 2nd. Royal Bank of Canada set a $218.00 price target on shares of Allergan and gave the company a buy rating in a report on Thursday, January 4th. Finally, Wells Fargo set a $245.00 price target on shares of Allergan and gave the company a buy rating in a report on Friday, January 5th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and fourteen have assigned a buy rating to the company. The company presently has an average rating of Hold and a consensus price target of $220.91.
NYSE:AGN opened at $158.51 on Tuesday. Allergan has a 52 week low of $142.81 and a 52 week high of $256.80. The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.06 and a current ratio of 1.16. The company has a market cap of $55,243.03, a PE ratio of 9.68, a PEG ratio of 1.13 and a beta of 1.18.
Allergan (NYSE:AGN) last posted its quarterly earnings results on Tuesday, February 6th. The company reported $4.86 EPS for the quarter, beating the Zacks’ consensus estimate of $4.74 by $0.12. Allergan had a negative net margin of 26.32% and a positive return on equity of 8.43%. The firm had revenue of $4.33 billion for the quarter, compared to analysts’ expectations of $4.28 billion. During the same quarter in the prior year, the company posted $3.90 earnings per share. The business’s revenue for the quarter was up 12.0% on a year-over-year basis. equities analysts predict that Allergan will post 15.59 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which was paid on Wednesday, March 28th. Shareholders of record on Wednesday, February 28th were given a $0.72 dividend. The ex-dividend date of this dividend was Tuesday, February 27th. This is an increase from Allergan’s previous quarterly dividend of $0.70. This represents a $2.88 annualized dividend and a yield of 1.82%. Allergan’s dividend payout ratio (DPR) is presently 17.61%.
In other Allergan news, CEO Brent L. Saunders purchased 3,300 shares of the firm’s stock in a transaction on Thursday, March 8th. The shares were acquired at an average cost of $152.53 per share, for a total transaction of $503,349.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Maria Teresa Hilado purchased 895 shares of the firm’s stock in a transaction on Thursday, March 15th. The stock was acquired at an average price of $167.39 per share, for a total transaction of $149,814.05. The disclosure for this purchase can be found here. Insiders acquired 8,095 shares of company stock worth $1,258,081 over the last quarter. Insiders own 0.36% of the company’s stock.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Avestar Capital LLC bought a new stake in shares of Allergan during the 4th quarter valued at $113,000. Focused Wealth Management Inc raised its position in shares of Allergan by 4,444.4% during the 4th quarter. Focused Wealth Management Inc now owns 818 shares of the company’s stock valued at $134,000 after purchasing an additional 800 shares during the period. Acropolis Investment Management LLC bought a new stake in shares of Allergan during the 4th quarter valued at $153,000. Field & Main Bank bought a new stake in shares of Allergan during the 4th quarter valued at $155,000. Finally, Captrust Financial Advisors bought a new stake in shares of Allergan during the 4th quarter valued at $175,000. Institutional investors and hedge funds own 77.95% of the company’s stock.
Allergan Company Profile
Allergan plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products that provide treatment for the central nervous system, gastroenterology, women's health and urology, ophthalmology, neurosciences, medical aesthetics, dermatology, plastic surgery, liver disease, inflammation, metabolic syndromes, and fibrosis, as well as Alzheimer's disease.
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.